Taiwan’s Bora Group has announced its acquisition of the contract development and manufacturing organization (CDMO) operations from Maryland-based MacroGenics for a total consideration of up to $127.5 million. This strategic move reflects Bora’s commitment to expanding its capabilities in the biopharmaceutical manufacturing sector, enhancing its portfolio and operational footprint.
The acquisition comes at a time when demand for robust CDMO services is surging, driven by increasing outsourcing trends among pharmaceutical companies seeking flexibility and expertise in production. By integrating MacroGenics’ established operations, Bora aims to leverage existing technologies and processes to improve efficiency and accelerate time-to-market for its clients.
This transaction not only positions Bora as a more competitive player in the global CDMO landscape but also underscores the ongoing consolidation trend within the industry, as companies seek to optimize resources and enhance service offerings in response to evolving market needs.
Start your 7-day trial and see what the database can do →
